Neurocrine Biosciences, Inc. (NBIX)
$135.91+0.58%Close
SELLRECOVERY · day 29
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $13.7B
- Beta
- 0.40
- P/E (TTM)
- 19.28
- Short % float
- 5.83%
- Days to cover
- 4.0
- SI change
- +17.9%
- 1W
- -5.27%
- 1M
- -9.41%
- vs SPY 1W
- -4.29%
- vs SPY 1M
- -11.27%
Industry peers
FMP comparable companies · ranked by market cap
- JAZZSELLJazz Pharmaceuticals plc$13.7BBEARQ 24$218.42-0.35%
- AXSMSELLAxsome Therapeutics, Inc.$8.7BCRISISQ 34$168.35+3.77%
- HLBBFH. Lundbeck A/S$5.4B$6.76
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 18$19.78+3.38%
- SUPNSELLSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.67-4.36%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 15$12.08-4.29%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 23$30.65-2.28%
- GHRSSELLGH Research PLC$1.4BCRISISQ 14$21.11-1.54%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NBIX?
- LOPJLB’s latest quantitative signal on Neurocrine Biosciences, Inc. (NBIX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is NBIX in?
- Neurocrine Biosciences, Inc. (NBIX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Neurocrine Biosciences, Inc. (NBIX) do?
- Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental …